The IGF-I suppression observed by the selective estrogen receptor modulators tamoxifen and raloxifen seems to correspond to those observed with oral estrogens: a randomized open-label study in 2018 reported that raloxifene could decrease serum IGF-1 level in acromegaly [49]. This evidence concerns the gene ESR1 and acromegaly.